we quick plan our will to on and year want financial our December provide to Today, status and I clinical agent our equity and updates a Hanmi quarter from the strategic activities update welcome From ended and program. facility, a for our for investment committed with through development XX, lead perspective, a XXXX, the Susan. luxeptinib financed by tuspetinib a Pharmaceutical. fourth during XXXX. on corporate cash on everyone from you, gleaned facility near-term Thank our we our ATM financial call long-term partner,
Payne, January closed financing placement in with proceeds year, Then along public a with program, and of lead million Hanmi CFO few us a and Fletcher more pivot private to additional $X details with financial this we million, $XX.X tuspetinib. Pharmaceutical. of $X.X gross CBO, room now breathing our million Mr. minutes. separate our of provide This inclusive to offering, a with provided I want in
as orally should tuspetinib, profile potent call convenient, or we is once TUS, why about with of it, anti-leukemic because daily It's is or AML. administered that you tuspetinib? myeloid leukemia, treatment developed excellent acute for kinase safety and being the activity inhibitor So care often an
And diagnosed this at newly care can how And we point. set this the believe patients of become AML tuspetinib-containing new treatment and genetic a standard we the of explain believe frontline today, why of a regimen arrived across triplet we'll for we subtypes. broader
we refractory tuspetinib doublet. in aware studies with AML been TUS/VEN with the to you're relapsed as and combination agent performing in refer a First, we've or which with that single as patients tuspetinib venetoclax,
inhibitor collectively newly treatment as agent venetoclax TUS/VEN/HMA hypomethylating development as includes now variable a have the as a from these the tuspetinib, referred the findings highest tuspetinib diagnosed and The combination therapy as the triplet. frontline the to of for studies led azacitidine, such priority. patients AML gleaned pursue triplet The triplet us to of BCL-X
the that triplet. that Because we our the our where for in the the impact on this precisely way. TUS/VEN/HMA we AML the a TUS/VEN/HMA believe all the great return from triplet safety And and go of and this greatest to should are our greatest agree impact, heard focusing tuspetinib is the the is These tuspetinib, to just KOLs and with be real of group a potential they of drug fact, activity KOLs In immediate the primarily has and patient investors. enthusiasm internal that they all greatest potential commercial deliver resources. have team focus to
its a plus survival who that are heard have them. primary triplet chemotherapy, exceed by of the long-term intensive to current of frontline At market the TUS/VEN/HMA the patients deaths the partners patient ineligible TUS/VEN/HMA patients life billion of improving standard to diversity is AML rates, aspect, and AML quality the application the the tuspetinib we relative of of impact frontline annually. to is responses, believe durability the care the across level, for response greatest and responses, estimated the the we've commercial in from potential VEN/HMA the the frontline interest frontline or can $X impact of therapy many of And AML to in
profiles Indeed, tuspetinib best combine with to the make is tuspetinib and of current agent standard VEN/HMA, the the efficacy date be the of to can safety, breadth care. which that us believe
to then to trough is While with tuspetinib the doublet path and the the trough through of and understand goal triplet, frontline transition the into for began after the tuspetinib components. to activity, contribution frontline move the therapy triplet safety single-agent tuspetinib program AML
with demonstrated trough, agents. achieved X we agent to populations relative II daily With Phase the observed dose liabilities XX XX in Tuspetinib's profile and of AML broad of selected was as single-agent median levels. patients for enrollment longer recommended single-agent without nonresponders patients single responding in completed activity key excellent therapy. milligrams across adverse overall a threefold safety many the once an survival competitor dose tuspetinib across We It the alterations. genetic seen
strong XX% level, treated patients been genotypes who referred have with therapy failed with CR/CRh a not dose see at XX-milligram high VEN-naive rate prior highly comer patients. of XX-milligram was the patients active, had to response high-quality dose level, among delighted the agent venetoclax were venetoclax. all the achieving We previously single with to as With few Notably, rates. tuspetinib's in responses
dose we as emerging our time. at dose the were category in a as escalated relapsed/refractory we that XX-milligram new However, point that VEN AML failure patients of level, saw above
of dose And increased in and VEN response as led single prior and are And refractory subsequent greater to in milligrams. the dramatically the including all Once then up agent. therapies, level. venetoclax-containing fell to to level proportion tuspetinib XXX a salvage level this the XXX-milligram dose rates patients dose more of than next in therapy, lower they XX% patients the XXX-milligram
combine this combine in the lining patient AML to models. we've targets there rationale conference relapsed/refractory that complementarity shown to for mechanistic us AML and described cells to provided TUS/VEN presentation, animal This resistance venetoclax with Plus, our tuspetinib-resistant tuspetinib relapsed/refractory past population. evaluate are venetoclax AML hypersensitive, In population. with we've help in venetoclax. silver the Fortunately, the change synergistically to the doublet a is fold venetoclax us mechanism to scientific X,XXX sensitive tuspetinib a how more in
In venetoclax, with XXX XX tuspetinib, have our of XX-milligram we a enrollment of in and XX-milligram with tuspetinib completed patients. TUS/VEN total milligrams combined with now doublet trial,
tuspetinib bone those And who of patients, AML broad with or doublet. therapies observed safety the the we leukemic profile observed we continue inhibitors mutations, agent therapy with majority prior blast First, across adverse activity evidence failed with tuspetinib with of who marrow the the therapy. including to a in venetoclax was prior including see failed of venetoclax. patients as patients prior FLTX diversity We excellent that single reductions maintained of
a promise dosage interest with population. been certain demonstrate great the resources we TUS/VEN a tuspetinib doublet would approval path TUS/VEN see the the defined partners. even those pursue has higher tuspetinib like subpopulation And become to available, for relapsed/refractory and treat relapsed/refractory for especially patients, as collaborators This failure We VEN the for doses of doublet effectively molecularly activity. of TUS/VEN of of for AML, TUS/VEN remains and potential doublet for a there standard potential to greater prior care patients of KOLs, the the high a become we if increase and doublet the source and accelerated and even and
However, therapy. triplet frontline in our chosen the resources in near on focus AML we have to term, the TUS/VEN/HMA
be to negativity value dosage plus So diagnosed the triplet initiate optimal in our which pilot frontline azacitidine rate, to study build data. tuspetinib, and next triplet possible a MRD to venetoclax driven newly be plus as tuspetinib CR/CRh will as of quickly select AML step will patients and by safety
studies After BD more of frontline frontline number Phase creating therapy appropriate that large compare to plan for for transition triplet, And doses the conversations the of of AML broader triplet of AML frontline and toxic companies effective, want control and our for durable, to a commercial registrational to mention into agents safety paradigm triplet the also the the I that patients. on need less newly efficacy we acting a selecting AML cocktails diagnosed point VEN/HMA they to focus more therapeutic of ongoing success. to the cornerstone with targeted patients. the emphasizing at pharma II
pilot patients we shortest partnerships TUS/VEN/HMA the study by AML period of earned a for frontline and create for the It's for of triplet performing support in development tuspetinib. clear can in capital that then data value greatest the can such time least tuspetinib of later-stage amount
minutes. clinical Officer, of Dr. provides process, perspectives strategic Medical So Chief framework with a with you few this and thought insights additional and in our our a you Bejar, provide will
also But our first, to want mention I luxeptinib. drug, other
lux, Enrollment or a having You that from study includes molecule that DLBCL milligrams. response dose and with treatment lymphomas, now the complete oral malignancy and tumor is patient of the lux and potent and study lymphoma patients and I GX patients impressive who follicular BID. in cancer to leukemias across refractory B-cell were has This to often the in dosing a levels In it, XXX kinase malignancies. trial, evaluable and milligrams shrinkage been XX% and a/b tumor for Phase patients lymphoid patients dose AML. highly including kinases a/b and we trial relapsed a for among CR B-cell myeloid inhibitor original for ranging of Phase a X hematologic B-cell XX the patients to in achieved this refractory SLL selectively with of across recall been treatment targets levels XXX reductions milligrams the in evaluated of milligrams patients. XXX formulation or dosed and from XXX in patients also This will as has operative relapsed call an bind I completed,
been enrollment ranging FLTX patients patients mutated trial the milligrams and completed. GX original patients and AML levels Bone evaluable marrow type of were has trial, AML AML XXX wild XXX dose across FLTX from XX% in and this to milligrams the evaluable formulation observed XX% reductions In BID. Likewise, the blast the now dosing of received of patients.
complete response the patient occurred or CR BID original formulation. XXX-milligram MRD-negative, GX the in X dosing an of relapsed/refractory addition, In AML with
Our formulation lux were clinical effectiveness data consistent report can but original drive patients we now the demonstrate has and GX a formulation not cancer also that levels the exposure the achieving GX that in desired AML consistently we in to completed. is Because of X, of new the was the hampered of formulation developed. And generation absorption responses. patients, been evaluation B-cell or luxeptinib, GX, active clinical
First, BID, levels tested the to different from across both XX a study was XXX including relapsed/refractory dose in in formulation milligrams of and different XX in dose AML dose XX single milligrams patients cancer milligrams with patients B-cell formulation GX was The milligrams. using bioavailability and patients, X XX and GX continuous X in a total BID dosing patients. levels, AML evaluated XXX then
be even of data approximately formulation than with levels daily tolerability GX the twice milligrams GX means achieved desired original our better tenfold formulation. X better X can benchmark Recent XXX formulation steady-state micromolar and formulation studies the the This choice lux. future will GX absorption at to plasma interestingly, for with exposure dosed and plasma that the formulation showed GX achieve the
and program, a these we findings see development viable and lux. a Collectively, with that formulation into focused lux for to should has drug advanced viable delighted future are demonstrate lux GX a a is clinical be formulation the
execute advanced we of populations unmet patient lux, molecularly that with are hematologic alternative strategy. lux malignancy potential steps paths and are next defined relapsed/refractory development seeking exploring any we And Regarding to to to treat collaborations now need. high
insights to for Resident clinical want call for the plans to and our his tuspetinib. Dr. and on Raf? now our comments Chief Officer over I turn KOL, data Medical and Bejar,
